Atossa Genetics Expands Breast Health Program With Mens’ Initiative

Gynecomastia is male breast enlargement and accompanying pain. It is the most common male breast disorder and is caused by a hormone imbalance where testosterone is low compared to estrogen. In prostate cancer treatment, testosterone is suppressed resulting is higher estrogen levels that usually triggers gynecomastia. Prophylactic breast bud irradiation is commonly used in prostate cancer patients, but must often be repeated. One recent study indicates that up to 90% of men taking androgen deprivation therapy suffer from gynecomastia and breast pain (Handoo Rhee, et al., October 18, 2014, BJU International).

According to the Mayo Clinic, although it can affect men at almost any age, it is most prevalent in men ages 50-69, affecting at least 1 in 4 men in this age group. Gynecomastia is caused by, among other things, any number of commonly prescribed medications, such as androgen deprivation therapy to treat prostate enlargement and prostate cancer; anti-anxiety medications; cancer treatments (chemotherapy), and some heart medications. Gynecomastia is not only painful and embarrassing, it can also cause men to stop taking these important medications.

There are no FDA-approved therapeutics for gynecomastia. Breast-bud irradiation, use of compression garments and plastic surgery are the most common approaches used to treat gynecomastia.

Seattle based Atossa Genetics Inc. (NasdaqCM: ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, recently announced that it has expanded its breast health program by launching a mens’ breast health initiative with enrollment opening in a Phase 1 study of its proprietary topical Endoxifen in men. Tamoxifen is an active metabolite of tamoxifen, an FDA approved drug for breast cancer in women. The objectives of the placebo-controlled, repeat dose study of 24 healthy male volunteers are to assess the pharmacokinetics of proprietary topical Endoxifen dosage forms over 28 days, as well as to assess safety and tolerability.

Dr. Steven Quay, Ph.D., MD, President and CEO of Atossa, commented that “Initiating a program for mens’ breast health is a natural extension for our proprietary Endoxifen, which has focused on women to date. This Phase 1 study of topical Endoxifen in men should serve as a foundation for future development into mens’ breast health, including male breast cancer and gynecomastia. Men being treated for prostate cancer currently have limited options to address the gynecomastia that is associated with their cancer treatment, such as breast-bud irradiation, estrogen suppression therapy and surgery.”

After reviewing the data obtained from our recently-completed Phase 1 study in women, expanding our program to include the men, whose breast health is often underserved, was a logical next step. We have progressed rapidly in this endeavor having engaged the necessary contract research organizations and having submitted and received approval to open the study for enrollment. This will be the first of other studies targeting mens’ breast health. We look forward to reporting progress on this study as well as the other anticipated studies we are commencing in 2018.”

The study is being conducted on behalf of Atossa by CPR Pharma Services Pty Ltd., Thebarton, SA, Australia.  CPR Pharma recently completed the successful Phase 1 study of Atossa’s oral and topical Endoxifen in women.

The American Cancer Society (ACS) estimates that approximately 266,000 women will be diagnosed with breast cancer in the United States this year and that approximately 41,000 will die from the disease. It is the second leading cause of cancer death in American women. Although about 100 times less common than women, breast cancer also affects men. The ACS estimates that the lifetime risk of men getting breast cancer is about 1 in 1,000; 2,550 new cases of invasive breast cancer will be diagnosed; and 480 men will die from breast cancer in 2018.

Similar to women, the treatment for male breast cancer is typically surgery (with or without radiation) and chemotherapy. Breast cancer in men is deadlier than breast cancer in women: men with early-stage breast cancer have a lower five-year survival rate than women and breast cancer in men tends to be detected at a later stage of development than women (Jon M. Greif, DO, FACS, et al., May 2012, American Society of Breast Surgeons). Although tamoxifen is the standard of care for women to prevent new and recurrent breast cancer, there is no FDA-approved treatment for male breast cancer.

Endoxifen Background

Oral tamoxifen has been widely used for over 40 years to both treat and prevent breast cancer. Tamoxifen, however, has significant drawbacks: First, it can cause side effects including headaches, nausea and early menopausal symptoms as well as rare but serious side effects such as cataracts, stokes and cancer of the uterus. Second, tamoxifen is a “pro-drug,” meaning that it must be processed by the liver in order to produce therapeutic (“active”) metabolites. The metabolite in tamoxifen that accounts for most of its therapeutic activity is called Endoxifen. Unfortunately, up to 50% of breast cancer survivors who are taking tamoxifen do not produce therapeutic levels of Endoxifen (meaning they are “refractory”) for a number of reasons, including that they, due to their genotype, do not have the requisite liver enzymes. Additionally, it can take from 50-200 days for tamoxifen to reach “steady-state” meaning that the drug may be providing little or no benefit for up to several months after starting treatment.

Atossa is developing topical Endoxifen for women with mammographic breast density, or MBD, and for men with gynecomastia or breast cancer. There is no FDA-approved therapeutic for gynecomastia and male breast cancer. They estimate that approximately ten million women in the United States have MBD, for which there is no FDA-approved treatment. Although oral tamoxifen is approved to prevent breast cancer in “high-risk” women, it is used by less than 5% of women with an increased risk of developing breast cancer because of the actual or perceived side effects and risks of tamoxifen. They believe their topical Endoxifen may provide an effective treatment for MBD because, unlike an oral medication, it is applied directly to the breast and penetrates the skin; it does not require metabolism by the liver; and it may produce fewer side effects than tamoxifen. Moreover, their topical Endoxifen may improve mammography accuracy and patient care by unmasking cancerous tumors that are otherwise hidden by breast density, and reduce the risks of over diagnosing potential tumors when more highly sensitive imaging methods are used.

Second, Atossa is developing oral Endoxifen for breast cancer patients who are refractory to tamoxifen. Approximately one million breast cancer patients take tamoxifen to prevent recurrent and new breast cancer; however, up to 50% of those patients are refractory to tamoxifen. They believe their Endoxifen may provide an effective treatment supplement or option for these refractory patients because Endoxifen, unlike tamoxifen, does not require liver metabolism.

Atossa  recently completed a comprehensive Phase 1 study in 48 healthy women in Australia using both the topical and oral forms of their proprietary Endoxifen. They concluded that all objectives were successfully met in both arms of the study: there were no clinically significant safety signals and no clinically significant adverse events and both the oral and topical Endoxifen were well tolerated. In the topical arm of the study, there were low but measurable Endoxifen levels detected in the blood in a dose-dependent fashion and in the oral arm of the study participants exhibited dose-dependent Endoxifen levels in published reports of the therapeutic range. The median time for patients in the study to reach the steady-state serum levels of Endoxifen while taking daily doses of oral Endoxifen was 7 days. Published literature indicates that it takes approximately 50-200 days for patients to reach steady-state Endoxifen levels when taking daily doses of oral tamoxifen. Finally, the median time for patients in the study to reach the maximum serum level of Endoxifen after taking Atossa’s oral Endoxifen ranged from 4 to 8 hours (depending on dose). The 4 mg dose of Endoxifen produced a maximum serum level of Endoxifen in 4 to 8 hours at levels above the generally accepted threshold for a therapeutic effect on estrogen-dependent breast cancer.

In September 2017, Atossa contracted Stockholm South General Hospital in Sweden to conduct a Phase 2 study of their topical Endoxifen. The primary endpoint is MBD reduction, as well as safety and tolerability. Atossa is planning to open this study in the first half of 2018 and to complete it in the second half of 2018. Atossa plans to commence a Phase 2 clinical study using their oral Endoxifen for patients who are refractory to tamoxifen. Atossa has retained a clinical research organization to manage the study and they plan to open the study in the first half of 2018 and to complete it in the second half of 2018.  Atossa has now opened enrollment in our Phase 1 study of topical Endoxifen in men.

To learn more about Atossa Genetics (ATOS) and to track its ongoing progress, please visit the Vista Partners Atossa Genetics Coverage Page.

Atossa Genetics Launches Mens’ Breast Health Program

SEATTLE, March 22, 2018– Atossa Genetics Inc., a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced …..

Read Full Article

“Fusion Delivered Outstanding Results Over The Course of 2017” – Matthew Rosen CEO

Fusion (FSNN), is a leading provider of integrated cloud solutions to small, medium and large businesses. Fusion’s advanced, proprietary cloud service platform enables the integration of leading edge solutions in the cloud, including cloud communications, contact center, cloud connectivity, and cloud computing. Fusion’s innovative, yet proven cloud solutions lower their customers’ cost of ownership, and deliver new levels of security, flexibility, scalability, and speed of deployment. In January 2018, Fusion acquired the intellectual property and substantially all of the other assets of IQMax, a pioneer in developing secure messaging, enterprise data integration and advanced cloud communications solutions
In February 2018, Fusion completed a public offering of 12,937,500 shares of its common stock at a price of $3.20 per share, for gross proceeds of $41.4 million and for net proceeds of $38.7 million (after underwriting discounts and commissions, but before estimated offering expenses payable by Fusion)

Today, Fusion announced financial results for its fourth quarter and full year ended December 31, 2017. Consolidated revenue grew 36% to $40.3 million, compared to $29.6 million in Q4 2016 while Business Services segment revenue grew 19% to $29.6 million, compared to $24.8 million in Q4 2016. Consolidated Full Year revenue grew 21% to $150.5 million, compared to $124.7 million in 2016, driven by a 32% increase in Business Services segment revenue to $117.3 million.

Matthew Rosen, Fusion’s Chief Executive Officer stated “Fusion delivered outstanding results over the course of 2017,” said Matthew Rosen, Fusion’s Chief Executive Officer. “Excluding the contribution from Apptix, the company achieved year-over-year revenue growth in Business Services for all four quarters, confirming that our strategy is working and demonstrating the strength of our value proposition in the marketplace. This performance was highlighted by Fusion’s strong growth and solid operational metrics in Business Services in the fourth quarter. We also saw sustained positive momentum in organic bookings and in the contract value of our backlog, which bodes well for the future as we convert these customer wins to revenue.

We have also made significant progress toward closing the Birch acquisition. Over the past several months, teams from both sides have been working closely together to develop detailed integration plans so that we will hit the ground running on Day One after the close. We also received overwhelming support for the transaction at our shareholder meeting in February. While the regulatory process has taken longer than expected, only one more state application requires approval for us to be in a position to close the transaction, and we expect to obtain this by the end of the first week of April.

Meanwhile, the debt syndication process remains extremely active, and we are as confident as ever in closing the financing. The lengthy regulatory approval process has given us a greater opportunity to work on achieving the best possible terms for Fusion, in light of both present and future opportunities to create shareholder value through acquisitions. We continue to feel very good about the deal today and believe we have a clear path to closing the financing in the near term.”

Michael Bauer, Fusion’s Chief Financial Officer stated, “Fusion’s strong year-over-year Adjusted EBITDA growth in the fourth quarter and for full year demonstrates our ability to successfully identify and integrate acquisitions. In 2017, Fusion achieved all of the cost synergies related to Apptix. With the additional liquidity from our recent equity offering, we believe that Fusion is well positioned for sustained future growth to create long-term value, leveraging the unique and compelling single source platform we have built over the past six years.”

To learn more about Fusion (Nasdaq: FSNN) and to track its progress please visit the Vista Partners Fusion (FSNN) Coverage Page.


Fusion Reports Fourth Quarter and Full Year 2017 Financial Results

NEW YORK, March 22, 2018– Fusion, a leading cloud services provider, today announced financial results for its fourth quarter and full year ended December 31, 2017.. Consolidated revenue grew 36% to $40.3 …..

Read Full Article

Intel’s Quarterly Cash Dividend Declared

Intel Corporation (INTC) seeks to expand the boundaries of technology to provide the most amazing experience possible. Intel designs, manufactures, and sells integrated digital technology globally.

Intel Corporation Board of Directors declared a quarterly dividend of $0.30 per share on the company’s common stock ($1.20 annual basis). The dividend is payable June 1, 2018 to those stockholders as of record at the close of business on May 7, 2018.

To learn more about Intel Corporation (INTC) and to track its progress please visit the Vista Partners Intel Corporation Coverage Page.

Intel Declares Quarterly Cash Dividend


Read Full Article

Cybersecurity Expert Christopher D. Young Elected to American Express Board of Directors

American Express Company (AXP), and its subsidiaries, provide customers and businesses globally with charge and credit payment card products and travel-related services. They look to enrich the lives of their customers and build business success.

Christopher D. Young, Chief Executive Officer of McAfee, LLC one of the largest cybersecurity brands, has been elected to the American Express Company Board of Directors. Young has led multiple cybersecurity efforts with companies such as Intel, Cisco, RSA, and AOL. He graduated cum laude from Princeton University and earned his MBA from Harvard Business School. He is a member of the President’s National Security Telecommunications Advisory Committee and formerly served on the Board of Trustees of Princeton University.

Chris’s leadership accomplishments at McAfee, his business experience and expert knowledge of technology and cybersecurity make him a terrific addition to our Board.” -Stephen J. Squeri, chairman and chief executive officer of American Express Company.

To learn more about American Express Company (AXP) and to continue to track its progress please visit the Vista Partners American Express Coverage Page.

American Express Company Elects Christopher D. Young to Board of Directors

Read Full Article

Diversified Resources Company BHP’s First Half Year Results

BHP is a world-leading resources company that extracts and processes minerals, oil and gas and their products are sold worldwide. Their global headquarters are in Melbourne, Australia. they operate under a Dual Listed Company structure with two parent companies (BHP Billiton Limited and BHP Billiton Plc) operated as if they were a single economic entity, which they refer to as BHP.  They are run by a unified Board and management. Their stated corporate purpose is to create long-term shareholder value through the discovery, acquisition, development and marketing of natural resources. They do this through their strategy: to own and operate large, long-life, low-cost, expandable, upstream assets diversified by commodity, geography and market.

They are among the world’s top producers of major commodities, including iron ore, metallurgical coal and copper. BHP also has substantial interests in oil, gas and energy coal.

Recently BHP reported results for the half year ended 31 December 2017.

BHP Chief Executive Officer, Andrew Mackenzie stated, “Higher commodity prices and a solid operating performance delivered free cash flow of US$4.9 billion. We used this cash to further reduce net debt and increase returns to shareholders through higher dividends. We are on track to deliver further productivity gains of US$2 billion by the end of the 2019 financial year as we secure improvements in both operating and capital productivity, aided by smarter technology application across our value chain. Our capital expenditure program remains focused on high-return, low-risk development opportunities in commodities where we see greatest potential. We remain firm in our resolve to maximise cash flow, maintain discipline and increase shareholder value and returns.”


Read Full Article

Johnson & Johnson Enters Binding Offer to Sell LifeScan, Inc. For Approx. $2.1 Billion

Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services.

Johnson & Johnson has received a binding offer from Platinum Equity to buy its LifeScan Business, which serves approximately 20 million patients globally in more than 90 countries. Platinum Equity is one of the leading private investment firms and LifeScan, Inc is a leader in blood glucose monitoring products. The offer is for approximately $2.1 billion and is subject to customary adjustments.

LifeScan realized 2017 net revenues of approximately $1.5 billion.

The end of the offer’s acceptance period will be on June 15, 2018, and if accepted is expected to close by the end of 2018.

To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.

Johnson & Johnson Announces Binding Offer from Platinum Equity to Acquire LifeScan, Inc.

NEW BRUNSWICK, N.J., March 16, 2018 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) today announced that it has received a binding offer from Platinum Equity, a leading private investment firm, to acquire its LifeScan business for approximately $2.1 billion, subject to customary adjustments. LifeScan, Inc. is a leader in blood gluco…..

Read Full Article

Dow 30 Component Travelers to Review First Quarter Results

The Travelers Companies, Inc. (TRV), a Dow 30 component,  is an insurance provider of property casualty insurance for home, auto, and business.

The Travelers Companies, Inc. will host a conference call on Tuesday, April 24, 2018 to review its first quarter 2018 results. After the webcast, a slide presentation, statistical supplement, and an audio broadcast will be available through the investor section of Travelers’ website.

The call can be accessed through webcast at or by calling 800.707.7427.

To learn more about The Travelers Companies, Inc. (TRV) and to continue to track its progress please visit the Vista Partners Travelers Companies, Inc. Coverage Page.

Read Full Article

Harvey Schwartz to Retire From Goldman Sachs

The Goldman Sachs Group, Inc.(GS) is one of the world’s leading investment bankers. They are a securities and investment management firm that offers a wide range of financial services with a diversified client base.

Goldman Sachs announced that the firm’s President and Co-chief Operating Officer, Harvey Schwartz, will retire April 20, 2018. Schwartz has been in this role since January 2017, and before that was the Chief Financial Officer for four years. He has been with the Goldmans Sachs Group since 1997 when he served as a vice president. Since then he has served in several roles including managing director andGlobal Head of Securities Division Sales.

Harvey has been a mentor to many, and his influence has made an indelible impact on generations of professionals at Goldman Sachs. I want to thank Harvey for all he’s done for the firm.” -Lloyd C. Blankfein, Chairman and CEO of Goldman Sachs.

Upon Harvey Schwartz’s retirement, David Solomon will serve as the sole President and Chief Operating Officer of The Goldman Sachs Group, Inc.

To learn more about The Goldman Sachs Group, Inc. (GS) and to continue to track its progress please visit the Vista Partners Goldman Sachs Group, Inc. Coverage Page.

Goldman Sachs | Press Releases – Harvey M. Schwartz to Retire From Goldman Sachs, David M. Solomon to Serve as Sole President and Chief Operating Officer


Read Full Article

Happy St. Patty’s Day Weekend! “Lucky Charms For You?” Vista Partners Weekly Market Update 3-17-18 Now Available!

Vista Partners has published “Lucky Charms For You?” Vista Partners Weekly Market Update 3-17-18   and is accessible on our Newsletters Page. Each issue is written by Managing Director, John Heerdink and speaks to the activities of the market, influencers and specific featured stories from Vista’s Coverage Universe that spans the Dow 30, International and Select Emerging Growth Companies.

Each weekly update issue is sent out via email directly to the thousands of investors around the world that have elected to be updated each week. Please “Join us” Today!

Stay Informed! Stay Competitive! It’s FREE & EASY to sign up.

Johnson & Johnson Vision Promotes the Patient Experience at FTC Workshop

Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services.

Peter Menziuso and Carol Lakkis represented Johnson & Johnson at the Federal Trade Commission’s public workshop in Washington D.C. where they emphasized the company’s obligation to eye health and patient safety.

The workshop was put on as part of the FTC’s 10-year review of the Contact Lens Rule. It provided stakeholders the opportunity to share feedback on how proposed changes can affect patient-doctor relationships and consumer access to contemporary contact lenses.

Menziuso and Lakkis emphasized the benefits of a booming contact lens marketplace that promotes patient experience and minimizes health-related risks.

Three things are critical to ensuring a healthy eye health community – both now and in the future. First, is continuing to promote the importance of the doctor-patient relationship and regular, comprehensive eye exams. Next, is making sure patients receive the exact contact lenses as prescribed, regardless of where they choose to purchase. And lastly, we believe that contact lens wearers deserve care consistent with the high standard of care they receive in their eye doctor’s office, regardless of where or how they receive it.” – Dr. Peter Menziuso, President Johnson & Johnson Vision Care, Inc. North America

To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.

Johnson & Johnson Vision Advocates on Behalf of Patients at FTC Public Workshop

WASHINGTON, March 7, 2018 /PRNewswire/ — Today, Peter Menziuso and Carol Lakkis, BScOptom, Ph.D., represented Johnson & Johnson Vision alongside fellow eye health advocates in Washington, D.C. to underscore the company’s commitment to eye health and patient safety during the Federal Trade Commission’s (FTC) public w…..

Read Full Article